Cargando…
The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiple...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828119/ https://www.ncbi.nlm.nih.gov/pubmed/36169332 http://dx.doi.org/10.1002/path.6012 |
_version_ | 1784867200136380416 |
---|---|
author | López‐Janeiro, Álvaro Villalba‐Esparza, María Brizzi, María Emilia Jiménez‐Sánchez, Daniel Ruz‐Caracuel, Ignacio Kadioglu, Ece Masetto, Ivan Goubert, Virginie Garcia‐Ros, David Melero, Ignacio Peláez‐García, Alberto Hardisson, David de Andrea, Carlos E |
author_facet | López‐Janeiro, Álvaro Villalba‐Esparza, María Brizzi, María Emilia Jiménez‐Sánchez, Daniel Ruz‐Caracuel, Ignacio Kadioglu, Ece Masetto, Ivan Goubert, Virginie Garcia‐Ros, David Melero, Ignacio Peláez‐García, Alberto Hardisson, David de Andrea, Carlos E |
author_sort | López‐Janeiro, Álvaro |
collection | PubMed |
description | Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD‐1, and PD‐L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune‐desert subtype, characterized by low immune cell densities. Tumor‐infiltrating lymphocyte (TIL)‐rich samples (4%) displayed high CD8(+) T‐cell infiltration, as well as a high percentage of CD8/PD‐1(+) cells. Immune‐exclusion samples (19%) displayed the lowest CD8(+) infiltration combined with high PD‐L1 expression levels in CK(+) tumor cells. In addition, they demonstrated high tumor cell spatial clustering as well as increased spatial proximity of CD8(+)/PD‐1(+) and CK/PD‐L1(+) cells. FOXP3 and macrophage‐rich phenotypes (3% and 4% of total samples) displayed relatively high levels of FOXP3(+) regulatory T‐cells and CD68(+) macrophages, respectively. These phenotypes correlated with clinical outcomes, with immune‐exclusion tumors showing an association with tumor relapse. When compared with prediction models built using routine pathological variables, models optimized with immune variables showed increased outcome prediction capacity (AUC = 0.89 versus 0.78) and stratification potential. The improved prediction capacity was independent of mismatch repair protein status and adjuvant radiotherapy treatment. Further, immunofluorescence results could be partially recapitulated using single‐marker immunohistochemistry (IHC) performed on whole tissue sections. TIL‐rich tumors demonstrated increased CD8(+) T‐cells by IHC, while immune‐exclusion tumors displayed a lack of CD8(+) T‐cells and frequent expression of PD‐L1 in tumor cells. Our results demonstrate the capability of the immune microenvironment to improve standard prediction tools in low‐grade, early‐stage endometrial carcinomas. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. |
format | Online Article Text |
id | pubmed-9828119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-98281192023-01-10 The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients López‐Janeiro, Álvaro Villalba‐Esparza, María Brizzi, María Emilia Jiménez‐Sánchez, Daniel Ruz‐Caracuel, Ignacio Kadioglu, Ece Masetto, Ivan Goubert, Virginie Garcia‐Ros, David Melero, Ignacio Peláez‐García, Alberto Hardisson, David de Andrea, Carlos E J Pathol Original Articles Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD‐1, and PD‐L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune‐desert subtype, characterized by low immune cell densities. Tumor‐infiltrating lymphocyte (TIL)‐rich samples (4%) displayed high CD8(+) T‐cell infiltration, as well as a high percentage of CD8/PD‐1(+) cells. Immune‐exclusion samples (19%) displayed the lowest CD8(+) infiltration combined with high PD‐L1 expression levels in CK(+) tumor cells. In addition, they demonstrated high tumor cell spatial clustering as well as increased spatial proximity of CD8(+)/PD‐1(+) and CK/PD‐L1(+) cells. FOXP3 and macrophage‐rich phenotypes (3% and 4% of total samples) displayed relatively high levels of FOXP3(+) regulatory T‐cells and CD68(+) macrophages, respectively. These phenotypes correlated with clinical outcomes, with immune‐exclusion tumors showing an association with tumor relapse. When compared with prediction models built using routine pathological variables, models optimized with immune variables showed increased outcome prediction capacity (AUC = 0.89 versus 0.78) and stratification potential. The improved prediction capacity was independent of mismatch repair protein status and adjuvant radiotherapy treatment. Further, immunofluorescence results could be partially recapitulated using single‐marker immunohistochemistry (IHC) performed on whole tissue sections. TIL‐rich tumors demonstrated increased CD8(+) T‐cells by IHC, while immune‐exclusion tumors displayed a lack of CD8(+) T‐cells and frequent expression of PD‐L1 in tumor cells. Our results demonstrate the capability of the immune microenvironment to improve standard prediction tools in low‐grade, early‐stage endometrial carcinomas. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2022-10-25 2022-12 /pmc/articles/PMC9828119/ /pubmed/36169332 http://dx.doi.org/10.1002/path.6012 Text en © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles López‐Janeiro, Álvaro Villalba‐Esparza, María Brizzi, María Emilia Jiménez‐Sánchez, Daniel Ruz‐Caracuel, Ignacio Kadioglu, Ece Masetto, Ivan Goubert, Virginie Garcia‐Ros, David Melero, Ignacio Peláez‐García, Alberto Hardisson, David de Andrea, Carlos E The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title | The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title_full | The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title_fullStr | The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title_full_unstemmed | The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title_short | The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
title_sort | association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828119/ https://www.ncbi.nlm.nih.gov/pubmed/36169332 http://dx.doi.org/10.1002/path.6012 |
work_keys_str_mv | AT lopezjaneiroalvaro theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT villalbaesparzamaria theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT brizzimariaemilia theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT jimenezsanchezdaniel theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT ruzcaracuelignacio theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT kadiogluece theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT masettoivan theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT goubertvirginie theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT garciarosdavid theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT meleroignacio theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT pelaezgarciaalberto theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT hardissondavid theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT deandreacarlose theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT lopezjaneiroalvaro associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT villalbaesparzamaria associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT brizzimariaemilia associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT jimenezsanchezdaniel associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT ruzcaracuelignacio associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT kadiogluece associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT masettoivan associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT goubertvirginie associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT garciarosdavid associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT meleroignacio associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT pelaezgarciaalberto associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT hardissondavid associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients AT deandreacarlose associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients |